JFL Life Sciences Complete Financial Statements
In FY2026, JFL Life Sciences (JFLLIFE) reported revenue ₹131 Cr, net profit ₹6 Cr and EPS ₹1.94, with a net profit margin of 4.6% and ROE of 13.0%. Full financial statements from FY2019 to FY2026 (8 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse JFLLIFE shareholding pattern to track promoter, FII and institutional holdings.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
JFLLIFE Revenue, Net Profit & EBITDA — Year-on-Year Growth
JFLLIFE YoY (March 2025 vs March 2026) — revenue +59.8%, net profit +50.0%, EBITDA +50.0%, expenses +62.2%. Also explore JFLLIFE share price charts to track price trends across different timeframes.
JFLLIFE Income Statement — Revenue, EBITDA & Net Profit
JFL Life Sciences revenue ₹131 Cr, EBITDA ₹12 Cr, net profit ₹6 Cr, EPS ₹1.94 (2026) — net profit margin 4.6%. For live price, earnings ratios and company overview, see JFLLIFE stock price BSE.
| Particulars | March 2026 | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 131 | 82 | 47 | 45 | 35 | 33 | 30 | 32 |
| Expenses | 120 | 74 | 42 | 39 | 28 | 31 | 28 | 31 |
| EBITDA | 12 | 8 | 5 | 6 | 6 | 2 | 2 | 1 |
| Operating Profit Margin % | 9.00% | 10.00% | 10.00% | 9.00% | 16.00% | 7.00% | 6.00% | 4.00% |
| Depreciation | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Profit Before Tax | 9 | 6 | 4 | 4 | 4 | 1 | 1 | 0 |
| Tax | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 |
| Net Profit | 6 | 4 | 3 | 3 | 3 | 1 | 0 | 0 |
| Earnings Per Share (₹) | 1.94 | 1.26 | 1.00 | 2.90 | 4.12 | 0.89 | 0.66 | 0.59 |
JFLLIFE Balance Sheet — Assets, Liabilities & Shareholders' Equity
JFLLIFE total assets ₹106 Cr, total equity ₹46 Cr, total liabilities ₹ Cr (2026) — ROE 13.0%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Total Assets | 106 | 72 | 57 | 49 | 48 | 29 | 24 | 16 |
| Current Assets | 92 | 60 | 44 | 41 | 39 | 21 | 18 | 14 |
| Fixed Assets | 15 | 12 | 13 | 7 | 7 | 7 | 5 | 3 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 60 | 44 | 42 | 41 | 23 | 19 | 14 |
| LIABILITIES | ||||||||
| Total Liabilities | ||||||||
| Current Liabilities | 7 | 1 | 1 | 2 | 9 | 8 | 1 | 3 |
| Non-Current Liabilities | ||||||||
| SHAREHOLDERS' EQUITY | ||||||||
| Total Equity | 46 | 40 | 36 | 32 | 11 | 7 | 5 | 5 |
| Share Capital | 33 | 33 | 11 | 11 | 8 | 1 | 0 | 0 |
| Reserves & Surplus | 13 | 7 | 25 | 21 | 3 | 6 | 5 | 5 |
JFLLIFE Cash Flow Statement — Operating, Investing & Financing
JFL Life Sciences operating cash flow ₹-4 Cr, investing ₹0 Cr, financing ₹4 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | -4 | 8 | -9 | 2 | -6 | 3 | -3 |
| Investing Activities | 0 | -6 | 1 | -1 | -2 | -3 | -1 |
| Financing Activities | 4 | -2 | 8 | -2 | 7 | 0 | 4 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 |